Synergistic Potential Of Bioactive Compounds Of Nut Grass Tuber Extract (Cyperusrotundus) As Anti-Leukemia Herbal Medicine

Agustini, S. M.; Tri Aini Fadjrin Juliani; Nimim; Patmawati

doi:10.22219/sm.Vol17.SMUMM2.18805

Authors

Agustini, S. M. University of Muhammadiyah Malang
Tri Aini Fadjrin Juliani
Nimim
Patmawati Patmawati

DOI:

https://doi.org/10.22219/sm.Vol17.SMUMM2.18805

Abstract

Leukemia treatment strategies have developed rapidly. Both the intensity of the dose and the duration of intensive treatment have been maximized after decades of trials optimizing chemotherapy options, dose intensity, and duration of treatment. The emergence of multidrug-resistant cancer cells (MDR) results in the higher costs needed in the treatment of AML patients. The purpose of this study was to identify and evaluate the potential of active compounds from Cyperus rotundus on the activity of the Acute Myeloid Leukemia (AML) cell line HL-60 APL through inhibition of proliferation, cell cycle, differentiation, and induction of apoptosis in the treatment of AML. The bioavailability of the compound to be taken orally was analyzed by Human Intestine Absorption (HIA+). Potential pathways inhibiting proliferation, cell cycle, differentiation, and induction of apoptosis in the treatment of AML were analyzed using a Structure-Activity Relationship approach with the PASS SERVER program. Pathway analysis was carried out using STITCH and Cytoscape v.3.5.1 programs. The study results showed that nutgrass has six active compounds quercetin, luteolin, apigenin, camphor, sitosterol, and gallic acid, synergizing the main pathway of cell activity (Pa>0.7).Conclusion of Cyperus rotundus extract has a high potential synergistically as an anti-leukemia herbal medicine.

Downloads

Download data is not yet available.

Author Biography

Agustini, S. M., University of Muhammadiyah Malang

Clinical Pathology Department, Medical Faculty, Muhammadiyah University of Malang

References

Jonas BA, Medeiros BC. Clinical presentation of acute myeloid leukemia. In: Garza JM, editor. Acute myeloid leukemia: signs/symptoms, classification and treatment options. Hauppauge, NY: Nova Science Publishers, Inc; 2015. p. 1-34.

Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-51.

Mrozek K, Marcucci G, Nicolet D, et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol. 2012;30:4515-23.

Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079-89.

Khaled S, Al Malki M, Marcucci G. Acute myeloid leukemia: biologic, prognostic, and therapeutic insights. Oncology (Williston Park). 2016;30:318-29.

Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366:1090-8.

Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059-74.

Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371:2477-87.

Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488-98.

Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med. 2012;4:149ra18.

Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548-53.

Reinisch A, Chan SM, Thomas D, Majeti R. Biology and clinical relevance of acute myeloid leukemia stem cells. Semin Hematol. 2015;52:150-64.

Jan M, Majeti R. Clonal evolution of acute leukemia genomes. Oncogene. 2013;32:135-40.

Wong TN, Ramsingh G, Young AL, et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature. 2015;518:552-5.

Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125:1367-76.

Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): an international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) [abstract]. Blood. 2015;126:6.

Stein E, DiNardo C, Altman J, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial [abstract]. Blood. 2015;126:323.

DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naïve patients with acute myeloid leukemia who are ≥ 65 years and not eligible for standard induction therapy [abstract]. Blood. 2015;126:327.

Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422-33.

Terwijn M, van Putten WL, Kelder A, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889-97.

Kayser S, Schlenk RF, Grimwade D, et al. Minimal residual disease-directed therapy in acute myeloid leukemia. Blood. 2015;125:2331-5.

Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33:1258-64.

Rollig C, Serve H, Huttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691-9.